Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Soon Woo Nam"

Article category

Keywords

Publication year

"Soon Woo Nam"

Letter to the Editor

Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung
Clin Mol Hepatol 2022;28(4):926-928.
Published online September 5, 2022
DOI: https://doi.org/10.3350/cmh.2022.0233

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
    Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen
    Clinical and Molecular Hepatology.2023; 29(1): 176.     CrossRef
  • Post-COVID-19 cholangiopathy: Systematic review
    Mazen Abdalla Rasheed, Vinícius Remus Ballotin, Lucas Goldmann Bigarella, Jonathan Soldera
    World Journal of Methodology.2023; 13(4): 296.     CrossRef
  • Forms of cholangitis to be considered after SARS-CoV-2 infection
    Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2022; 28(4): 929.     CrossRef
  • 4,922 View
  • 82 Download
  • 2 Web of Science
  • Crossref
Case Report

Viral hepatitis

Favorable effect of corticosteroids in treating acute-on-chronic liver failure underlying chronic hepatitis B
Hyeji Kim, Jung Hyun Kwon, Yong Hee Kim, Soon Woo Nam, Jong Yul Lee, Jeong Won Jang
Clin Mol Hepatol 2018;24(4):430-435.
Published online November 27, 2017
DOI: https://doi.org/10.3350/cmh.2017.0016
Acute-on-chronic liver failure (ACLF) occurs in the presence of a chronic liver disease or cirrhosis, and often results from exacerbation of chronic hepatitis B (CHB). The efficacy of corticosteroid treatment in ACLF patients with underlying CHB remains unclear. We report the case of a 50-year-old woman who experienced ACLF due to CHB exacerbation and was treated with a combination of corticosteroids and nucleot(s)ide analogue (NUC). The patient showed rapid decompensation due to CHB exacerbation. Three months of antiviral therapy produced no improvement in liver function. Combination therapy with corticosteroids and NUC was started, which did result in improvement of liver function. This case shows that the combined therapy of corticosteroids and NUC can be effective in treating ACLF due to CHB exacerbation.

Citations

Citations to this article as recorded by  Crossref logo
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
    Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin
    Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584.     CrossRef
  • Hypomethylation of thymosin β4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure
    He Wang, Yu Qian, Jing-Wen Wang, Yu Fang, Yu-Chen Fan, Hui-Hui Liu, Kai Wang
    International Health.2023; 15(1): 19.     CrossRef
  • Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care
    Cyriac Abby Philips, Kamna Kakkar, Moby Joseph, Praveen Kumar Yerol, Rizwan Ahamed, Sasidharan Rajesh, Philip Augustine
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • 13,013 View
  • 262 Download
  • 3 Web of Science
  • Crossref